The treatment of severe falciparum malaria.
Identifieur interne : 000623 ( PubMed/Corpus ); précédent : 000622; suivant : 000624The treatment of severe falciparum malaria.
Auteurs : A P HallSource :
- Transactions of the Royal Society of Tropical Medicine and Hygiene [ 0035-9203 ] ; 1977.
English descriptors
- KwdEn :
- Adult, Antimalarials (therapeutic use), Chloroquine (administration & dosage), Chloroquine (therapeutic use), Erythrocytes (pathology), Humans, Infusions, Parenteral, Malaria (drug therapy), Malaria (parasitology), Malaria (pathology), Male, Plasmodium falciparum, Quinine (administration & dosage), Quinine (therapeutic use).
- MESH :
- chemical , administration & dosage : Chloroquine, Quinine.
- chemical , therapeutic use : Antimalarials, Chloroquine, Quinine.
- drug therapy : Malaria.
- parasitology : Malaria.
- pathology : Erythrocytes, Malaria.
- Adult, Humans, Infusions, Parenteral, Male, Plasmodium falciparum.
Abstract
In severe falciparum malaria there is a pathophysiological cascade beginning with changes in the parasitized red blood cells which induce intermediate effects, in turn contributing to dysfunction of several organs. A low serum albumin is a common but often unrecognized finding which may contribute to oedema especially in the lung and brain. The only irreversible complication in falciparum malaria is the acute respiratory distress syndrome, manifested by cyanosis and rapid breathing, basically distinct from acute pulmonary oedema caused by therapeutic overhydration. The pathophysiology of falciparum malaria may be complex but the treatment is simple. Drugs, other than antimalarials, are rarely needed. Guidelines for cholorquine or quinine dosage in severe disease are proposed; each drug is given at a dose of 5 to 10 mg/kg in 10 ml/kg of fluid as an intravenous infusion in four hours at a frequency of dosing every 12 to 24 hours. When the disease has been brought under control the treatment should be changed from the intravenous to the oral route.
DOI: 10.1016/0035-9203(77)90032-3
PubMed: 339421
Links to Exploration step
pubmed:339421Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The treatment of severe falciparum malaria.</title><author><name sortKey="Hall, A P" sort="Hall, A P" uniqKey="Hall A" first="A P" last="Hall">A P Hall</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1977">1977</date><idno type="RBID">pubmed:339421</idno><idno type="pmid">339421</idno><idno type="doi">10.1016/0035-9203(77)90032-3</idno><idno type="wicri:Area/PubMed/Corpus">000623</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000623</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The treatment of severe falciparum malaria.</title><author><name sortKey="Hall, A P" sort="Hall, A P" uniqKey="Hall A" first="A P" last="Hall">A P Hall</name></author></analytic><series><title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title><idno type="ISSN">0035-9203</idno><imprint><date when="1977" type="published">1977</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antimalarials (therapeutic use)</term><term>Chloroquine (administration & dosage)</term><term>Chloroquine (therapeutic use)</term><term>Erythrocytes (pathology)</term><term>Humans</term><term>Infusions, Parenteral</term><term>Malaria (drug therapy)</term><term>Malaria (parasitology)</term><term>Malaria (pathology)</term><term>Male</term><term>Plasmodium falciparum</term><term>Quinine (administration & dosage)</term><term>Quinine (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Chloroquine</term><term>Quinine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimalarials</term><term>Chloroquine</term><term>Quinine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Malaria</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Malaria</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Erythrocytes</term><term>Malaria</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Humans</term><term>Infusions, Parenteral</term><term>Male</term><term>Plasmodium falciparum</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In severe falciparum malaria there is a pathophysiological cascade beginning with changes in the parasitized red blood cells which induce intermediate effects, in turn contributing to dysfunction of several organs. A low serum albumin is a common but often unrecognized finding which may contribute to oedema especially in the lung and brain. The only irreversible complication in falciparum malaria is the acute respiratory distress syndrome, manifested by cyanosis and rapid breathing, basically distinct from acute pulmonary oedema caused by therapeutic overhydration. The pathophysiology of falciparum malaria may be complex but the treatment is simple. Drugs, other than antimalarials, are rarely needed. Guidelines for cholorquine or quinine dosage in severe disease are proposed; each drug is given at a dose of 5 to 10 mg/kg in 10 ml/kg of fluid as an intravenous infusion in four hours at a frequency of dosing every 12 to 24 hours. When the disease has been brought under control the treatment should be changed from the intravenous to the oral route.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">339421</PMID><DateCompleted><Year>1978</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-9203</ISSN><JournalIssue CitedMedium="Print"><Volume>71</Volume><Issue>5</Issue><PubDate><Year>1977</Year></PubDate></JournalIssue><Title>Transactions of the Royal Society of Tropical Medicine and Hygiene</Title><ISOAbbreviation>Trans. R. Soc. Trop. Med. Hyg.</ISOAbbreviation></Journal><ArticleTitle>The treatment of severe falciparum malaria.</ArticleTitle><Pagination><MedlinePgn>367-78</MedlinePgn></Pagination><Abstract><AbstractText>In severe falciparum malaria there is a pathophysiological cascade beginning with changes in the parasitized red blood cells which induce intermediate effects, in turn contributing to dysfunction of several organs. A low serum albumin is a common but often unrecognized finding which may contribute to oedema especially in the lung and brain. The only irreversible complication in falciparum malaria is the acute respiratory distress syndrome, manifested by cyanosis and rapid breathing, basically distinct from acute pulmonary oedema caused by therapeutic overhydration. The pathophysiology of falciparum malaria may be complex but the treatment is simple. Drugs, other than antimalarials, are rarely needed. Guidelines for cholorquine or quinine dosage in severe disease are proposed; each drug is given at a dose of 5 to 10 mg/kg in 10 ml/kg of fluid as an intravenous infusion in four hours at a frequency of dosing every 12 to 24 hours. When the disease has been brought under control the treatment should be changed from the intravenous to the oral route.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>A P</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trans R Soc Trop Med Hyg</MedlineTA><NlmUniqueID>7506129</NlmUniqueID><ISSNLinking>0035-9203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>A7V27PHC7A</RegistryNumber><NameOfSubstance UI="D011803">Quinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007263" MajorTopicYN="N">Infusions, Parenteral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008288" MajorTopicYN="N">Malaria</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010963" MajorTopicYN="N">Plasmodium falciparum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011803" MajorTopicYN="N">Quinine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>128</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1977</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1977</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1977</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">339421</ArticleId><ArticleId IdType="doi">10.1016/0035-9203(77)90032-3</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000623 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000623 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:339421
|texte= The treatment of severe falciparum malaria.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:339421" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |